Polyrizon (NASDAQ:PLRZ) Cut to “Sell” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen downgraded shares of Polyrizon (NASDAQ:PLRZ – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on Polyrizon

Polyrizon Stock Performance

Shares of PLRZ stock opened at $11.32 on Friday. The firm has a 50 day moving average price of $12.18 and a two-hundred day moving average price of $12.97. Polyrizon has a 12-month low of $2.88 and a 12-month high of $18.20.

Polyrizon Company Profile

(Get Free Report)

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Featured Stories